Background: TIM-1, a member of the T cell immunoglobulin and mucin domain (TIM) gene family was implicated as an asthma susceptibility gene in previous studies. TIM-1 is selectively expressed on activated CD4+ T cells and its expression is sustained preferentially on T helper type 2 (Th2) cells, which suggests that TIM-1 is associated with T cell differentiation and the development of Th2-biased immune response. Methods: In order to evaluate the effects of the promoter polymorphism in the TIM-1 gene on asthma susceptibility in a Chinese Han population, 2 promoter polymorphisms, –416G>C and –1454G>A, from 2 alternative promoter regions, were genotyped in 409 unrelated asthma patients and 305 healthy controls by using polymerase chain reaction and restriction fragment length polymorphism. Also, we analyzed the functional significance of –416G>C using the luciferase reporter gene assay. Results: We found that –416G>C was associated with asthma susceptibility in our study population (χ2 = 9.88, p = 0.002, odds ratio 1.41, 95% confidence interval 1.14–1.75). No statistically significant difference in the distribution of genotype and allele frequency of the –1454G>A site was observed. The –416G>C substitution increased the transcriptional activity of the TIM-1 gene. Conclusion: Our findings suggest that the –416G>C variation site in the human TIM-1 promoter region is associated with asthma susceptibility in a Chinese Han population.

Keywords:
TIM-1, Promoter, Polymorphism, Single nucleotide polymorphism, Asthma
1.
Renauld JC: New insights into the role of cytokines in asthma. J Clin Pathol 2001;54:577–589.
2.
Umetsu DT, Mclntire JJ, Akbari O, Macaubas C, DeKruyff RH: Asthma: an epidemic of dysregulated immunity. Nature Immunol 2001;3:715–720.
3.
Kere J, Laitinen T: Positionally cloned susceptibility genes in allergy and asthma. Curr Opin Immunol 2004;16:689–694.
4.
Malerba G, Pignatti PF: A review of asthma genetics: gene expression studies and recent candidates. J Appl Genet 2005;46:93–104.
5.
McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT, DeKruyff RH: Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001;2:1109–1116.
6.
McIntire JJ, Umetsu SE, Macaubas C, Hoyte EG, Cinnioglu C, Cavalli-Sforza LL, Barsh GS, Hallmayer JF, Underhill PA, Risch NJ, Freeman GJ, DeKruyff RH, Umetsu DT: Immunology: hepatitis A virus link to atopic disease. Nature 2003;425:576.
7.
Chae SC, Song JH, Heo JC, Lee YC, Kim JW, Chung HT: Molecular variations in the promoter and coding regions of human Tim-1 gene and their association in Koreans with asthma. Hum Immunol 2003;64:1177–1182.
8.
Chae SC, Song JH, Lee YC, Kim JW, Chung HT: The association of the exon 4 polymorphisms of Tim-1 gene with allergic diseases in a Korean population. Biochem Biophys Res Commun 2003;312:346–350.
9.
Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, Schou C, Krishnaswamy G, Beaty TH: Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994;264:1152–1156.
10.
Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA, Levitt RC: Genetic susceptibility to asthma – bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995;333:894–900.
11.
Noguchi E, Shibasaki M, Arinami T, Takeda K, Maki T, Miyamoto T, Kawashima T, Kobayashi K, Hamaguchi H : Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med 1997;156:1390–1393.
12.
Yokouchi Y, Nukaga Y, Shibasaki M, Noguchi E, Kimura K, Ito S, Nishihara M, Yamakawa-Kobayashi K, Takeda K, Imoto N, Ichikawa K, Matsui A, Hamaguchi H, Arinami T: Significant evidence for linkage of mite-sensitive childhood asthma to chromosome 5q31-q33 near the interleukin 12 B locus by a genome-wide search in Japanese families. Genomics 2000;66:152–160.
13.
Walley AJ, Wiltshire S, Ellis CM, Cookson WO: Linkage and allelic association of chromosome 5 cytokine cluster genetic markers with atopy and asthma associated traits. Genomics 2001;72:15–20.
14.
Myers JH, Sabatos CA, Chakravarti S , Kuchroo VK: The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med 2005;11:362–369.
15.
Gao PS, Mathias RA, Plunkett B, Togias A, Barnes KC, Beaty TH, Huang SK: Genetic polymorphisms of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population. J Allergy Clin Immunol 2005;115:982–988.
16.
Noguchi E, Nakayama J, Kamioka M, Ichikawa K, Shibasaki M, Arinami T: Insertion/deletion coding polymorphisms in hHAVcr-1 are not associated with atopic asthma in the Japanese population. Genes Immun 2003;4:170–173.
17.
Li JS, Liu QJ, Wang P, Li HC, Wei CH, Guo CH, Gong YQ: Absence of association between two insertion/deletion coding genetic polymorphisms of TIM-1 gene and asthma in Chinese Han population. Int J Immunogenet 2006 33:417–422.
18.
Chae SC, Park YR, Song JH, Shim SC, Yoon KS, Chung HT: The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population. Immunogenetics 2005;56:696–701.
19.
Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005 15:97–98.
20.
Hyde-DeRuyscher RP, Jennings E, Shenk T: DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res 1995;23:4457–4465.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.